infarct size; ischemia-reperfusion injury; apoptosis; epidermal growth factor receptor RESOLVIN E1 [5S,12R,18R-trihydroxyeicosapentaenoic acid (RvE1)] is an anti-inflammatory mediator derived from the oxygenation of the -3 polyunsaturated fatty acid eicosapentaenoic acid (EPA). It was first identified in inflammatory tissue exudates in a model of spontaneous resolution in mice fed EPA and later shown to accelerate the resolution of a localized acute inflammation (5, 39) . Its formation can follow one of two routes: 1) via cyclooxygenase (COX)2 that has been acetylated at Ser 516 by aspirin and 5-lipoxygenase (LOX) (2, 40) or 2) an initial oxidation step by cytochrome P-450 monooxygenase followed by 5-LOX oxidation in an aspirin-independent manner (3). RvE1 has been shown to promote the resolution of inflammation not only in acute but also experimental models of chronic inflammation, including colitis (4), periodontitis (19) , and lung inflammation (1, 24) . Similar -3-derived mediators, resolvin D1 and neuroprotectin D1, have been shown to protect against renal (12) and brain (32) ischemia-reperfusion injury by reducing the number of infiltrating leukocytes, blocking Toll-like receptor-mediated activation of macrophages (12) , and preventing NF-B and COX2 activation in neuronal cells (32) . On the other hand, NF-B and COX2 activation are essential for mediating myocardial protection by ischemic and various forms of pharmacological preconditioning (23, 50) . COX2 activation is also involved in postconditioning-mediated protection against reperfusion injury (37) . In the present study, we asked whether RvE1, administered before reperfusion, could limit myocardial infarct size (IS). A limitation of the in vivo model is a lack of separation between a direct protective effect on the cardiomyocytes and an indirect effect due to inactivation or reduced migration of leukocytes into the myocardial tissue. Therefore, the H9c2 cardiac embryonic myoblast line was used to assess whether RvE1 has direct protective effects on cardiomyocytes, independent of the acute immune response in this model. The cell line also allowed us to assess the effects of RvE1 on the expression and activation of several proteins known to mediate protection against reperfusion injury, including prosurvival mediators [the phosphoinositide 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) pathway, ERK1/2, p38, inducible NOS (iNOS), and COX2] and proapoptotic pathways (including caspase-3 and BAX) (11, 20, 22, 23) . Finally, we assessed whether the protective effects of RvE1 are dependent on EGF receptor (EGFR) tyrosine kinase activation, as it has recently been reported that RvE1 promotes epithelial wound healing through EGFR transactivation (51) .
METHODS

Animal Care
All animals received humane care in compliance with National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) . Experiments were conducted on male Sprague-Dawley rats. This study was approved by the University of Texas Medical Branch Institutional Animal Care and Use Committee.
In Vivo Experiments
Rats (290 -310 g) were anesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (6 mg/kg), intubated, and ventilated (fraction of inspired O 2: 30%). The left carotid artery was cannulated for measuring blood pressure and heart rate. The chest was opened, and the left coronary artery was encircled with a suture and ligated for 30 min. Ischemia was verified by regional dysfunction and discoloration of the ischemic zone. Isofluorane (1-2.0% titrated to effect) was added to maintain anesthesia. After 30 min of ischemia, the coronary artery snare was released, and myocardial reperfusion was verified by a change in the color of the myocardium. After 30 min of reperfusion, the carotid artery catheter was pulled out, and the artery was ligated. Subcutaneous buprenorphine (0.1 mg/kg) was administered, the chest was closed, and rats were allowed to recover from anesthesia. After 4 h of reperfusion, rats were reanesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (6 mg/kg). The coronary artery was reoccluded. Evans blue dye (3%) was injected into the right ventricle, and rats were euthanized under deep anesthesia (200 mg/kg Nembutal).
The prespecified exclusion criteria were as follows: lack of signs of ischemia during coronary artery ligation, lack of signs of reperfusion after release of the snare, prolonged ventricular arrhythmia with hypotension, and area at risk (AAR) Յ 10% of the left ventricular weight.
Treatment protocols. PROTOCOL 1. At 28 min of ischemia, rats received RvE1 (0.03, 0.1, or 0.3 mg/kg iv dissolved in PBS) or PBS alone (control) into the tail vein. PROTOCOL 2. Thirty minutes before the coronary artery occlusion, rats received intravenous AG-1478, an EGFR tyrosine kinase inhibitor, at 3 mg/kg dissolved in DMSO (0.1%) or DMSO (0.1%) alone. At 28 min of ischemia, all rats received RvE1 (0.3 mg/kg iv) dissolved in PBS.
IS. Hearts were excised, and the left ventricle was sliced transversely into six sections. Slices were incubated for 10 min at 37°C in 1% buffered (pH 7.4) 2,3,5-triphenyltetrazolium chloride (TTC), fixed in 10% formaldehyde, and photographed to identify the AAR (uncolored by blue dye), IS (unstained by TTC), and nonischemic zones (colored by blue dye). The AAR and IS in each slice were determined by planimetry, converted into percentages of the whole for each slice, and multiplied by the weight of the slice. The results were summed to obtain the weight of the myocardial AAR and IS.
All assessments of myocardial AAR and IS were done by an observer masked to the treatment group.
Assessment of inflammatory cell infiltration. Rats were exposed to 30 min of ischemia and 4 h of reperfusion, as described above. At 28 min of ischemia, rats received RvE1 (0.3 mg/kg iv) or PBS alone (control). Hearts were cut transversely, fixed in 10% formalin solution, and stained with hemoxylin-eosin. The number of white blood cells in the postischemic zone was counted as the sum of the cell counts in three different ϫ20 fields. There were six animals in each group.
Immunoblot analysis. Hearts were rinsed in cold PBS (pH 7.4) containing 0.16 mg/ml heparin to remove red blood cells and clots, frozen in liquid nitrogen, and stored at Ϫ80°C for further analyses. Myocardial samples from the border of the risk zone of the anterior wall of the left ventricular wall exposed to ischemia-reperfusion (as delineated by the blue dye) or from the anterior wall of control hearts not exposed to ischemia were homogenized in lysis buffer [containing (in mM) 25 Tris·HCl (pH 7.4), 0.5 EDTA, 0.5 EGTA, 1 PMSF, 1 DTT, 25 NaF, and 1 Na 3VO4 with 1% Triton X-100, 2% SDS, and 1% protease inhibitor cocktail]. The lysate was centrifuged at 10,000 g for Hypoxia was induced by layering mineral oil over a thin film of hypoxic media (prebubbled with N2 gas), which covered the cells for 16 h. The hypoxic media was a HEPES-buffered medium that contained (in mmol/l) 139 NaCl, 4.7 KCl, 0.5 MgCl2, 0.9 CaCl2, and 5 HEPES (pH 7.4). The hypoxia medium was replaced by fresh medium (complete growth medium) and followed by 2 h of reoxygenation. Hypoxia/reoxygenation-induced cell death was measured by counting trypan blue-stained cells and expressed as a percentage of the total cells counted, based on the ability of live cells to exclude trypan blue. For each well, 250 -300 cells were counted.
Cell viability was measured by a 3-[4,5-yl]-2,5-diphenyltetrazolium bromide (MTT) cell viability assay. Cells were treated with MTT (0.5 mg/ml) for 4 h at 37°C. Attached cells were lysed in 2-isopropanol containing 0.04 M HCl, and the amount of metabolized MTT was determined using a microplate reader. Data are expressed as percentages of the control NSIR group.
Fig. 2. Samples of immunoblots (A) and densitometric analysis of Ser
473 phosphorylated (P-)Akt (B), Thr 308 P-Akt (C), total Akt (D), P-ERK1/2 (E), and total ERK1/2 (F) in the border zone of hearts exposed to ischemia-reperfusion (IR) and treated with vehicle (control) or RvE1 (0.1 or 0.3 mg/kg). The myocardium of rats not exposed to IR and rats that received vehicle served as controls. *P Ͻ 0.001 vs. non-IR control; #P Ͻ 0.001 vs. IR control.
The degree of intracellular DNA fragmentation (apoptosis) was determined using a cell death detection ELISA kit according to the manufacturer's instructions. This kit detects levels of cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) after induced cell death (30) .
PI3K activity. A commercially available ELISA kit was used. Briefly, cells were homogenized in the presence of protease inhibitors. Protein concentrations were determined using Bradford reagent (BioRad Laboratories). Enzyme activity was expressed as amounts of phosphatidylinositol 3,4,5-trisphosphate (in pmol/mg protein) using the kit according to the manufacturer's instructions.
Casapase-3 activity. We used the Caspase-3 Colorimetric Protease Assay Kit according to the manufacturer's instructions. H9c2 cells prepared after respective treatments were lysed in lysis buffer [containing 1% Triton X-100, 0.32 M sucrose, 5 mM EDTA, 1 mM PMSF, 1 M aprotinin, 1 M leupeptin, 2 mM DTT, and 10 mM Tris·HCl (pH 8.0)] on ice for 30 min and centrifuged at 15,000 g for 15 min. Assays were performed by incubating 200 g protein of cell lysate in 100 l of reaction buffer containing 5 l of caspase-3 substrate (4 mM DEVD-pNA) in 96-well plates. The reaction buffer contained 1% Nonidet P-40, 20 mM Tris·HCl (pH 7.5), 137 mM N-acetylcysteine, and 10% glycerol. Lysates were incubated at 37°C for 2 h. Samples were incubated in the dark and measured with a microplate reader at an absorbance of 405 nm.
COX activity. Samples were homogenized in cold buffer [containing 0.1 M Tris·HCl (pH 7.8) and 1 mM EDTA] and centrifuged at 10,000 g for 15 min at 4°C, and the supernatant was collected and stored on ice. The assay kit measures the peroxidase activity of COX, assayed colorimetrically by monitoring the appearance of oxidized N,N,N=,N=-tetramethyl-p-phenylenediamaine at 590 nm. Each sample was tested in triplicate (the first without an inhibitor; the second with DuP-697, a specific COX2 inhibitor; and the third with Sc560, a specific COX1 inhibitor). COX1 activity was calculated as the difference between total COX activity in the sample without an inhibitor and the sample with Sc560, and COX2 activity was calculated as the difference between total COX activity in the sample without an inhibitor and the sample with DuP-697.
NOS activity. Cells were homogenized in a buffer [containing 25 mM Tris·HCl (pH 7.4), 1 mM EDTA, and 1 mM EGTA] and centrifuged at 10,000 g for 15 min. The supernatant, containing the soluble enzyme iNOS, and the pellet, containing membrane-bound eNOS and neuronal NOS [calcium-dependent NOS (cNOS)] were separated. The pellet was resuspended in homogenization buffer. NOS activity was determined by measuring the conversion of [L- 14 C]arginine to [L- 14 C]citrulline using a commercial kit. To assess cNOS activity, CaCl2 was added to the samples. To assess calcium-independent (ciNOS) activity, CaCl2 was omitted from the solution. NOS activity was defined in counts per minute.
Immunoblot analysis. Cells were homogenized in lysis buffer [containing (in mM) 25 Tris·HCl (pH 7.4) 0.5 EDTA, 0.5 EGTA, 1 PMSF, 1 DTT, 25 NaF, and 1 Na3VO4 with 1% Triton X-100, 2% SDS, and 1% protease inhibitor cocktail]. The lysate was centrifuged at 10,000 g for 15 min at 4°C. The resulting supernatants were collected. Immunoblot analysis was performed as described above for the in vivo experiments. Data are expressed as percentages of expression in the control group.
Immunoprecipitations. Cells were homogenized in 0.5 ml of lysis buffer [containing (in mM) 10 HEPES (pH 7.4), 20 KCl, 5 MgCl2, and 0.2 EDTA] at 4°C and centrifuged at 14,000 g in a precooled centrifuge for 15 min. The supernatant fraction was transferred to a fresh centrifuge tube. 6A7 Bax antibody, specific for amino acids 12-24 of the human Bax sequence (active Bax) (27, 46) , was added at a concentration of 40 nM, and immunoprecipitation was performed overnight on a rotator. Immunoprecipitates were collected by incubating with protein G-Sepharose for 2 h followed by pulse centrifugation (5 s in the microcentrifuge at 14,000 rpm). The supernatant was used to assess the concentrations of inactive Bax. , and anti-cleaved caspase-3 antibodies and AG-1478 were from Cell Signaling (Beverly, MA). Anti-␤ actin, anti-Bax, and anti-6A7 (product no. B8429) antibodies were from Sigma (St. Louis, MO). Anti-COX2 antibodies and ELISA kits for NOS and COX activities were from Cayman Chemicals (Ann Arbor, MI). Goat anti-mouse IgG and goat anti-rabbit IgG horseradish peroxidase-conjugated antibodies from were Southern Biotech (Birmingham, AL). The Caspase-3 Colorimetric Protease Assay Kit was from BioSource (Hopkinton, MA). The MTT cell respiration assay kit was purchased from R&D Systems (Minneapolis, MN), the Cell Death Detection ELISA kit was from Roche Applied Science (Indianapolis, IN), and the ELISA kit for PI3K activity from Echelon Biosciences (Salt Lake City, UT). 
Statistical Analysis
Data are presented as means Ϯ SE. ANOVA with the Sidak correction for multiple comparisons was applied for the results of protocol 1 and an unpaired t-test in protocol 2 to compare the different groups. Differences in heart rate and mean blood pressure were compared using two-way repeated-measures ANOVA with HolmSidak multiple-comparison procedures. Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
In Vivo Experiments
Protocol 1. Forty rats were included in protocol 1; none died or were excluded. Body weight, left ventricular weight, and the size of the ischemic AAR were comparable among the groups (Table 1) . IS was dose dependently reduced and was significantly smaller in the 0.1 and 0.3 mg/kg RvE1-treated groups than in the control group (Fig. 1A) . RvE1 did not affect mean blood pressure (Fig. 1B) or mean heart rate (Fig. 1C) .
LEUKOCYTE INFILTRATION. Four hours after reperfusion, the average white blood cell count in the postischemic zone of the control group was 634 Ϯ 22 cells versus 64 Ϯ 3 cells in the 0.3 mg/kg RvE1-treated group (P Ͻ 0.00001).
Protocol 2. Twelve animals were included in protocol 2; none died or were excluded. Body weight, left ventricular weight, and the size of the ischemic AAR were comparable between the two groups ( Table 1 ). In the presence of AG-1478, RvE1 failed to limit IS (Table 1) .
IMMUNOBLOT ANALYIS. Four animals were included in each group. Ischemia-reperfusion increased the myocardial levels of Ser 473 phospho-Akt, Thr 308 phospho-Akt, and phospho-ERK1/2 without altering the levels of total Akt or total ERK1/2 levels (Fig. 2) . RvE1 dose dependently increased Ser 473 phospho-Akt, Thr 308 phospho-Akt, and phospho-ERK1/2 levels without affecting total Akt or total ERK1/2 levels.
Cleaved caspase-3 was undetectable in the myocardium of control animals not exposed to ischemia-reperfusion. Ische- mia-reperfusion increased cleaved caspase-3 levels (Fig. 3) . RvE1 dose dependently attenuated this increase.
In Vitro Experiments
Experiment 1. TRYPAN BLUE UPTAKE. RvE1 did not affect cell death under normoxic conditions (NSIR; Fig. 4A ). RvE1 decreased cell death in cells exposed to SI in a dose-dependent fashion (Fig. 4B) . A maximal effect was achieved at a concentration of 100 nM. RvE1 also decreased cell death in cells exposed to SIR in a dose-dependent fashion (Fig. 4C) . A maximal effect was achieved at a concentration of 100 nM. Each experiment was repeated six times.
CELL VIABILITY (MTT ASSAY). RvE1 did not affect cell viability under normoxic conditions (NSIR; Fig. 4D ). RvE1 increased cell viability in cells exposed to SI in a dose-dependent fashion (Fig. 4E) . A maximal effect was achieved at a concentration of 100 nM. RvE1 increased cell viability in cells exposed to SIR in a dose-dependent fashion (Fig. 2F) . A maximal effect was achieved at a concentration of 100 nM. Each experiment was repeated eight times.
APOPTOSIS. RvE1 did not affect the rate of apoptosis under normoxic conditions (NSIR; Fig. 4G ) but did decrease apoptosis in cells exposed to SI (Fig. 4H) and SIR (Fig. 4I ) in a dose-dependent fashion, with a maximal effect at 100 nM. Each experiment was repeated six times.
PI3K ACTIVITY. Both SI and SIR increased PI3K activity (Fig. 5A ). RvE1 (100 nM) had no effect on PI3K activity in cells not exposed to SIR (NSIR); however, RvE1 further increased PI3K activity after SI and SIR. Each experiment was repeated four times.
CASPASE-3 ACTIVITY. RvE1 (100 nM) had no effect on caspase-3 activity in cells not exposed to SIR (NSIR ; Fig. 5B) ; however, RvE1 significantly attenuated the increase in caspase-3 activity seen after SI and SIR. Each experiment was repeated four times. NOS ACTIVITY. RvE1 (100 nM) had no effect on cNOS activity in cells not exposed to SIR (NSIR; Fig. 5C ). cNOS activity increased in cells exposed to SI and SIR. RvE1 significantly augmented the increase in cNOS activity seen after SI and SIR. RvE1 (100 nM) had no effect on ciNOS activity in cells not exposed to SIR (NSIR; Fig. 5D ). ciNOS activity increased in cells exposed to SI and SIR. RvE1 significantly attenuated the increase in ciNOS activity seen after SI and SIR. Each experiment was repeated six times.
COX ACTIVITY. SI and SIR did not affect COX1 activity (data not shown). RvE1 had no effect on COX1 activity in cells not Fig. 5 . H9c2 cells incubated with PBS (control) or RvE1 (100 nM) and subjected to 18 h of incubation under normoxic conditions (NSIR), 16 h of hypoxia (SI), or 16 h of hypoxia and 2 h of reoxygenation (SIR). A: phosphoinositide 3-kinase (PI3K) activity. B: caspase-3 activity. Data are expressed as percentages of control NSIR activity. C: RvE1 (100 nM) had no effect on calcium-dependent nitric oxide synthase (cNOS) activity in cells not exposed to SIR (NSIR). cNOS activity increased in cells exposed to SI and SIR. RvE1 significantly augmented the increase in cNOS activity seen after SI and SIR. cpm, Counts per minute. D: RvE1 (100 nM) had no effect on calcium-independent NOS (ciNOS) activity in cells not exposed to SIR (NSIR). ciNOS activity increased in cells exposed to SI and SIR. RvE1 significantly attenuated the increase in ciNOS activity seen after SI and SIR. E: cyclooxygenase (COX)2 activity was low in cells not exposed to SIR (NSIR). There were no differences between cells treated with or without RvE1. SI, and especially SIR, increased COX2 activity. RvE1 significantly attenuated this increase. *P Ͻ 0.05 vs. NSIR control; #P Ͻ 0.05, RvE1 vs. control. exposed to SIR (NSIR) and in those exposed to SI or SIR (data not shown). COX2 activity was low in cells not exposed to SIR (NSIR), and there were no differences between cells treated with or without RvE1. SI, and especially SIR, increased COX2 activity. RvE1 significantly attenuated this increase (Fig. 5E) . Each experiment was repeated six times.
IMMUNOBLOT ANALYSIS. SI and SIR did not affect total Akt levels (Fig. 6) . RvE1 had no effect on total Akt levels. On the other hand, SI and SIR increased the levels of both Ser 473 phospho-Akt and Thr 308 phospho-Akt (Fig. 6 ). RvE1 significantly augmented this increase. Each experiment was repeated six times.
SI and SIR did not affect total ERK1/2 levels (Fig. 7) . RvE1 had no effect on total ERK1/2 levels. In contrast, SI and SIR increased phospho-ERK1/2 levels. RvE1 significantly augmented this increase.
SI and SIR did not affect total eNOS levels (Fig. 7) . RvE1 had no effect on total eNOS levels. SI and SIR significantly increased Ser 1177 phospho-eNOS levels (Fig. 7) . RvE1 had no effect on cells not exposed to SIR; however, it significantly increased phospho-eNOS levels in cells exposed to SI or SIR. SI and SIR significantly increased COX2 levels (Fig. 7) . RvE1 did not alter COX2 levels in cells not subjected to SI. However, RvE1 significantly attenuated increase indicated by SI, SIR.
Immunoblottings were done with anti-total caspase-3 antibodies. RvE1 had no effect on activated caspase-3 levels in cells not exposed to ischemia (NSIR; Fig. 8 ). Each experiment was repeated four times. SI and SIR significantly increased caspase-3 activation. RvE1 blocked this increase. Activated caspase-3 levels in cells treated with RvE1 and exposed to SI or SIR were not different from those found in NSIR control cells.
SI, SIR, and RvE1 did not affect total p38 levels (Fig. 8) ; however, Thr 180 /Tyr 182 phospho-p38 levels were increased in cells exposed to SI and SIR. Each experiment was repeated four times. RvE1 attenuated this increase in cells exposed to SI and SIR without affecting phospho-p38 levels in cells not exposed to ischemia (NSIR).
SI and SIR increased Bax activation. RvE1 attenuated this effect (Fig. 8E ). Experiments were repeated four times.
Experiment 2. TRYPAN BLUE UPTAKE. Exposure to the EGFR tyrosine kinase inhibitor AG-1478 increased cell death, whereas RvE1 decreased cell death, compared with the control group (Fig. 9A) . AG-1478 blocked the protective effect of RvE1. Cell death in the combined treatment group was comparable with that in the control group. AG-1478 and RvE1 did not affect total Akt and total ERK1/2 levels. In contrast, AG-1478 mildly decreased the levels of Thr 308 phospho-Akt and phospho-ERK1/2 compared with the control group, whereas RvE1 induced a significant increase (Fig. 9) . AG-1478 blocked the effect of RvE1 on both Akt and ERK1/2 phosphorylation. Each experiment was repeated six times.
DISCUSSION
RvE1, an -3 polyunsaturated fatty acid-derived endogenous oxidation product, dose dependently protected against reperfusion injury in this open-chest rat model of ischemiareperfusion when administered at the clinically relevant time point before reperfusion. At a single dose of 0.3 mg/kg, RvE1 reduced IS by 70% compared with the control group without affecting mean blood pressure or heart rate ( Fig. 1) , an effect that is equal to or even larger than reported with similar interventions. Sparing of the myocardium at the time of reperfusion could be due to either prevention of early leukocyte migration into the myocardium, which is an effect ascribed to RvE1 in acute models of inflammation (4, 39), or direct protective effects on myocardial cells. It has been reported that other -3-derived resolvins and protectins, including the docosahexaenoic acid-derived product neuroprotectin D1, have direct effects on neuronal cell cultures, including a dampening of the host tissue immune response, and have also been shown to protect retinal pigmented epithelial cells from oxidative stress-induced apoptosis (35) .
The present experiments confirm that RvE1 prevented leukocyte diapedesis with a 90% reduction in infiltration into the postischemic zone 4 h after reperfusion. Reperfusion after ischemia is well documented to be accompanied by rapid leukocyte migration into the reperfused tissue and is considered to be a major contributor to reperfusion-induced damage (28) . However, the prevention of leukocyte infiltration may not fully explain the marked myocardial sparing, as events leading to cell death occur very rapidly after the start of reperfusion. Most of the literature concerning RvE1 deals with the control of inflammation and notably an accelerated resolution of inflammation (2, 4, 5, 19, 40 -42) , but the time course of inflammation resolution is very different from the immediate effects seen in this model. Furthermore, the role of inflammatory cells, in particular neutrophils, in mediating reperfusion injury has been questioned (6), and research is now increasingly focusing on the cellular pathways intrinsic to cardiomyocytes. A direct myocardial protective effect of RvE1 was confirmed in vitro using the cardiac embryonic myoblast cell line H9c2, both during SI and hypoxia/reoxygenation (SIR) injury (Fig. 4) . The effect was concentration dependent, and a maximal effect of 40% reduction in myocardial cell death was observed at 100 nM. Of note, RvE1 had no detectable effect on survival or apoptosis in cells incubated under normoxic conditions (NSIR). The effective concentrations in vitro are readily achievable plasma concentrations with the doses administered in the in vivo experiments (rat pharmacokinetic data on intravenous administration of RvE1; unpublished observations).
It is well known that the PI3K/Akt and ERK1/2 pathways are involved in the amelioration of reperfusion injury, and the powerful cardioprotection seen with postconditioning, adenosine, opioids, and bradykinins has been linked to increased phosphorylation of Akt and ERK1/2 (6, 20 -23) . The immunoblot data from hearts subjected to ischemia-reperfusion in the absence and presence of RvE1confirmed that RvE1 activates the same pathways. Akt and ERK1/2 phosphorylation were also confirmed in the H9c2 cell line, together with downregulation of caspase-3, which also was observed in the in vivo experiments, suggesting that RvE1 may act more broadly on survival pathways than some other pharmacological interventions that confer protection against reperfusion injury (Figs. 2, 6, and 7) . The similar pathway regulation in both the rat heart and in rat embryonic cardiomyocytes suggests that the relevant RvE1-dependent pathways are developed in the cell line and allow its further use in investigations of additional pathways that might be involved, although its embryonic state could confer certain limitations.
In the H9c2 cell line, RvE1 attenuated not only caspase-3 activity but also the expression of activated Bax (6A7). In our in vitro model, caspase-3 was activated during SI without further activation during SIR. While it is commonly believed that apoptosis plays a role in reperfusion injury and during ischemia cells die due to necrosis, the activation of proapoptotic pathways, including caspase-3, during ischemia before reperfusion has been previously described (8, 10, 13, 15, 36) . Proteins from the Bcl-2 family are upstream regulators of caspases, and the present experiments cannot differentiate between a direct effect or an indirect effect of RvE1 on caspase-3 regulation, although Bcl-2-independent activation of caspase-3 has been reported (33) .
Activation of eNOS by phosphorylation is essential for the protective effects of delayed ischemic preconditioning (9) and statins (50) . It has also been suggested that eNOS is involved in postconditioning (20) . Indeed, RvE1 increased the levels of phospho-eNOS (Fig. 7) , consistent with augmented cNOS activity (Fig. 5) . Surprisingly in the context of reperfusion, RvE1 attenuated iNOS (ciNOS) activity and COX2 expression and activity (Figs. 5 and 7) , as both iNOS and COX2 activation are considered essential for the protective effects of the delayed form of ischemic preconditioning (45) and the IS-limiting effects of statins (7, 50) . Eicosanoids, both COX2 dependent, such as PGI 2 (37) , and COX2 independent, such as 11,12-epoxyeicosatrienoic acid and 14,15-epoxyeicosatrienoic acid (16, 17) , have been reported to reduce myocardial IS. However, the role of iNOS and COX2 in mediating immediate protection against reperfusion injury (such as postconditioning), in contrast to a more prolonged stimulus such as delayed ischemic preconditioning or pretreatment with statins, is less established (23, 37) . We (49) have previously shown that pioglitazone limits IS in iNOS Ϫ/Ϫ mice and wild-type mice treated with N-nitro-L-arginine methyl ester, a nonspecific NOS inhibitor, suggesting that there are iNOS-and COX2-independent pathways of mediating survival. Moreover, we (48) have recently shown that the protective effect of sitagliptin, a dipeptidyl peptidase IV inhibitor, is independent of COX2.
Inhibition of p38 during ischemia reduces ischemia-reperfusion injury and limits IS (31, 34) . It has been suggested that inhibition of p38 mediates the protective effect of postconditioning (43) , and, in agreement with previous findings, we found that RvE1 inhibited p38 phosphorylation in cells exposed to SI and SIR (Fig. 8) . In contrast to the present study, Zhang et al. (51) reported that RvE1 increased p38 phosphorylation in immortalized human corneal epithelial cells and that wound healing in that model was p38 activation dependent. However, the corneal cells were not exposed to the levels of stress known with SI/SIR injury. RvE1 did not affect phosphop38 levels in H9c2 cells not exposed to SI or SIR, suggesting that the effect of RvE1 on p38 activation is both cell type and condition dependent.
In the experiments using human corneal epithelial cells, wound closure through the stimulation of cell migration, and the associated increases in Akt and p38 phosphorylation by RvE1, was linked to EGFR transactivation and RvE1-mediated release of heparin-binding EGF-like growth factor (HB-EGF) (51) . The EGFR is expressed on cardiomyocytes (18), including H9c2 cells (38) , and EGFR activation leads to Akt and ERK1/2 phosphorylation. The role of EGFR activation in myocardial protection against ischemia-reperfusion injury is not clear. HB-EGF activation of the EGFR is essential for mediating the effects of ACh on ROS generation and Akt phosphorylation in cardiomyocytes, which are necessary for mediating the protective effects of ischemic preconditioning (28) . Interestingly, however, AG-1478 does not block the protective effects of ischemic preconditioning (25) and AChinduced cardioprotection (29) in the isolated rabbit heart. Krieg et al. (29) suggested that the transactivation of the EGFR may be ligand independent. On the other hand, Foster et al. (14) showed that AG-1478 blocks the myocardial IS-limiting effects of the specific ␦-opioid receptor agonist [D-Ala 2 -DLeu 5 ]enkephalin (DADLE). Moreover, AG-1478 prevented the DADLE-induced increase in the phosphorylation of Akt and ERK1/2 in the isolated rabbit heart (14) . Postischemic administration of HB-EGF reduces brain IS in the rat (26) . Thus, the role of HB-EGF and/or EGFR activation may depend on the type of stimulus, but, in general, there is overwhelming experimental support for a beneficial role of EGFR transactivation in preventing ischemia-reperfusion damage. More recently, Uetani et al. (44) reported that overexpression of an uncleavable mutant of HB-EGF augmented cell death and apoptosis in H9c2 cells under normoxic, and especially hypoxic, conditions. Inactivated HB-EGF increased caspase-3 activity, ROS accumulation, and JNK activity (44) . The results of the last three studies are in agreement with our findings that the protective effects of RvE1 against hypoxia (SI) and hypoxia/reoxygenation (SIR) are EGFR dependent and that the activation of the prosurvival kinases Akt and ERK1/2 and inactivation of the proapoptotic pathways are also dependent on EGFR transactivation. However, the data do not conclusively show that HB-EGF mediates EGFR activation by RvE1, but the available information on transactivation, including the corneal epithelial cell data, suggests this to be the case (51). The exact mechanism through which RvE1 activates the myocardial EGFR as well as the signaling pathway involved is subject to further studies.
Limitations
Although we showed, both in vivo and in vitro, that the protective effect of RvE1 was blocked by AG-1478, this is not a proof that HB-EGF is directly involved. Using the only commercially available ELISA kit for human HB-EGF (catalog no. DY259, R&D Systems), we were not able to detect HB-EGF in the supernatants of the H9c2 cell cultures (rat origin). It might be that AG-1478, a tyrosine kinase inhibitor, has other non-EGFR-dependent effects.
We showed RvE1 activated the prosurvival pathway mediators PI3K, Akt, ERK1/2, and eNOS and attenuated the activation of the proapoptotic mediator caspase-3. Yet, we have not established a cause and effect. Further studies are needed to delineate the exact signaling pathway of RvE1 in mediating the protection against ischemia-reperfusion.
In the in vitro experiments, we used the H9c2 embryonic myoblast line. Obviously, there are differences between these embryonic cells and adult cardiomyocytes. We decided to use this model over adult cardiomyocyte cell cultures to eliminate the possibility that inflammatory cells would contaminate the cultures and affect the results.
Conclusions
RvE1, an anti-inflammatory mediator derived from the essential -3 fatty acid eicosapentaenoic acid, has a direct protective effect on cardiomyocytes against ischemia-reperfusion injury and limits IS when administered intravenously just before reperfusion. The magnitude of the tissue-sparing effect when RvE1 is administered at reperfusion indicates that RvE1 may have potential clinical applications in the treatment of acute myocardial infarction. Its protective effect seems to be dependent on transactivation of the EGFR and is associated with the activation of prosurvival pathways (Akt and ERK1/2) and inhibition of apoptosis. The data also suggest that stressdependent pathways may need to be activated for the host tissue, in this case, the cardiomyocyte, to respond to the protective effects of RvE1. Further studies should be conducted to investigate the long-term effects of RvE1 on cardiac function and remodeling postmyocardial infarction and to define the exact mechanisms by with RvE1 activates the prosurvival pathways and inhibits the proapoptotic pathways.
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